接受优特克单抗治疗的克罗恩病患者发生宫内胎儿死亡和流产：病例报告及文献综述
Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.
作者信息
Venturin C, Nancey S, Danion P, Uzzan M, Chauvenet M, Bergoin C, Roblin X, Flourié B, Boschetti G
机构信息
Department of Gastroenterology, Lyon-Sud hospital, Hospices Civils de Lyon, Université Lyon1, Lyon, France.
INSERM U1111, Centre International de Recherche en Infectiologie, Lyon, France.
出版信息
BMC Gastroenterol. 2017 Jun 19;17(1):80. doi: 10.1186/s12876-017-0633-6.
Abstract
BACKGROUND
Ustekinumab is a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 which is involved in the pathogenesis of several inflammatory diseases. Ustekinumab is approved for psoriasis and psoriatic arthritis treatment and has been successfully evaluated in phase II and III trials for patients with Crohn's disease (CD).
CASE PRESENTATION
We report here the case of a patient who became pregnant during treatment with ustekinumab for a refractory CD and which ended in miscarriage.
CONCLUSION
Ustekinumab is a relatively new pharmacotherapy and in addition to this clinical case, we reviewed the published literature concerning the use of this treatment during pregnancy and its consequences on pregnancy and fetus outcome.
摘要
背景
优特克单抗是一种全人源单克隆抗体，可作用于参与多种炎症性疾病发病机制的白细胞介素（IL）12和23的p40亚基。优特克单抗已被批准用于治疗银屑病和银屑病关节炎，并已在克罗恩病（CD）患者的II期和III期试验中得到成功评估。
病例报告
我们在此报告一例患者，该患者在使用优特克单抗治疗难治性CD期间怀孕，最终流产。
结论
优特克单抗是一种相对较新的药物疗法，除了本临床病例外，我们还回顾了已发表的有关该治疗在孕期的使用及其对妊娠和胎儿结局影响的文献。
相似文献
1
Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.接受优特克单抗治疗的克罗恩病患者发生宫内胎儿死亡和流产：病例报告及文献综述
BMC Gastroenterol. 2017 Jun 19;17(1):80. doi: 10.1186/s12876-017-0633-6.
2
Ustekinumab for the treatment of Crohn's disease.优特克单抗用于治疗克罗恩病。
Expert Rev Gastroenterol Hepatol. 2016 Sep;10(9):989-94. doi: 10.1080/17474124.2016.1215912. Epub 2016 Jul 28.
3
Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.英夫利昔单抗治疗期间长期免疫抑制药物治疗的难治性严重克罗恩病患者的间变大细胞 T 细胞淋巴瘤：病例报告及文献复习。
J Crohns Colitis. 2019 Oct 28;13(11):1470-1473. doi: 10.1093/ecco-jcc/jjz084.
4
Update on ustekinumab for the treatment of Crohn's disease.优特克单抗治疗克罗恩病的最新进展
Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013.
5
Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review.白细胞碎裂性血管炎与乌司奴单抗相关：一例克罗恩病患者的病例报告及文献复习。
J Crohns Colitis. 2020 Feb 10;14(2):274-276. doi: 10.1093/ecco-jcc/jjz128.
6
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.皮下注射乌司奴单抗可为三分之二对肿瘤坏死因子拮抗剂治疗抵抗的克罗恩病患者带来临床获益。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30.
7
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.优特克单抗治疗克罗恩病：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016.
8
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.乌司奴单抗和抗白细胞介素-23 制剂在克罗恩病中的应用。
Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013.
9
Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.定位乌司奴单抗在克罗恩病中的治疗地位：从临床证据到临床实践。
J Crohns Colitis. 2017 Oct 1;11(10):1258-1266. doi: 10.1093/ecco-jcc/jjx079.
引用本文的文献
1
Pregnancy and Inflammatory Bowel Disease: A Special Combination.妊娠与炎症性肠病：一种特殊组合
Middle East J Dig Dis. 2023 Oct;15(4):222-230. doi: 10.34172/mejdd.2023.350. Epub 2023 Oct 30.
2
IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.炎症性肠病与母亲身份：一段贯穿受孕、妊娠及之后的历程。
J Clin Med. 2023 Sep 25;12(19):6192. doi: 10.3390/jcm12196192.
3
Pregnancy in Patients with Inflammatory Bowel Diseases-A Literature Review.炎症性肠病患者的妊娠——文献综述
Life (Basel). 2023 Feb 9;13(2):475. doi: 10.3390/life13020475.
4
Therapy of PsO in Special Subsets of Patients.特殊患者亚组中银屑病的治疗。
Biomedicines. 2022 Nov 10;10(11):2879. doi: 10.3390/biomedicines10112879.
5
Oversight and Management of Women with Psoriasis in Childbearing Age.生育年龄女性银屑病的监管与管理。
Medicina (Kaunas). 2022 Jun 9;58(6):780. doi: 10.3390/medicina58060780.
6
Safety Prediction of Infants Born to Mothers with Crohn's Disease Treated with Biological Agents in the Late Gestation Period.妊娠晚期接受生物制剂治疗的克罗恩病母亲所生婴儿的安全性预测
J Anus Rectum Colon. 2021 Oct 28;5(4):426-432. doi: 10.23922/jarc.2021-021. eCollection 2021.
7
Shared decision making in pregnancy in inflammatory bowel disease: design of a patient orientated decision aid.炎症性肠病孕妇的共同决策：以患者为导向的决策辅助工具的设计。
BMC Gastroenterol. 2021 Jul 30;21(1):302. doi: 10.1186/s12876-021-01853-y.
8
The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU.炎症性肠病药物在妊娠和哺乳期的安全性：GETECCU的DUMBO注册研究方案
Therap Adv Gastroenterol. 2021 Jun 3;14:17562848211018097. doi: 10.1177/17562848211018097. eCollection 2021.
9
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road.患有风湿性疾病的女性在孕期和哺乳期使用生物制剂：前行中的安全性临床证据。
Front Pharmacol. 2021 Feb 11;12:621247. doi: 10.3389/fphar.2021.621247. eCollection 2021.
10
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.2020 年炎症性肠病循证临床实践指南。
J Gastroenterol. 2021 Jun;56(6):489-526. doi: 10.1007/s00535-021-01784-1. Epub 2021 Apr 22.
本文引用的文献
1
Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.妊娠期间使用肿瘤坏死因子抑制剂和优特克单抗治疗银屑病：病例系列
Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12454. Epub 2017 Jan 10.
2
Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.妊娠期间使用优特克单抗治疗克罗恩病：一例病例报告及文献综述
J Clin Pharm Ther. 2017 Apr;42(2):234-236. doi: 10.1111/jcpt.12492. Epub 2016 Dec 22.
3
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.乌司奴单抗治疗难治性克罗恩病：西班牙在大型多中心开放标签队列中的经验
Inflamm Bowel Dis. 2016 Jul;22(7):1662-9. doi: 10.1097/MIB.0000000000000842.
4
Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis.一名克罗恩病合并矛盾性银屑病患者在接受长期优特克单抗治疗后成功获得妊娠结局
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e191-e192. doi: 10.1111/jdv.13499. Epub 2015 Nov 11.
5
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.皮下注射乌司奴单抗可为三分之二对肿瘤坏死因子拮抗剂治疗抵抗的克罗恩病患者带来临床获益。
Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30.
6
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.用于诱导克罗恩病缓解的抗IL-12/23 p40抗体。
Cochrane Database Syst Rev. 2015 May 5(5):CD007572. doi: 10.1002/14651858.CD007572.pub2.
7
Pregnancy during Ustekinumab Treatment for Severe Psoriasis.使用优特克单抗治疗重度银屑病期间怀孕
Dermatology. 2015;231(2):103-4. doi: 10.1159/000380880. Epub 2015 Mar 17.
8
Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.一名患有斑块状银屑病和疱疹样脓疱病的患者在接受乌司奴单抗治疗期间意外怀孕。
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):488-90. doi: 10.1111/jdv.12872. Epub 2014 Nov 21.
9
Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester.两名在孕早期接触乌司奴单抗的患者的妊娠结局。
Australas J Dermatol. 2014 Aug;55(3):235-6. doi: 10.1111/ajd.12214.
10
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.皮下注射优特克单抗治疗抗TNF耐药性克罗恩病——麦吉尔大学的经验
J Crohns Colitis. 2014 Nov;8(11):1516-22. doi: 10.1016/j.crohns.2014.06.005. Epub 2014 Jul 1.
Zotero 插件